Baxalta Opens New R&D CenterBy
Baxalta Incorporated, the biopharmaceutical company spun off from Baxter earlier this year, has opened its Global Innovation Center in Cambridge, Massachusetts. The center is located in Kendall Square and will act as the innovation hub of the company's global infrastructure.
Baxalta's innovation efforts are focused on the development of therapies in hematology, immunology, and oncology. The company's approach to expanding its pipeline is based on an external innovation model, sourcing compounds externally through in-licensing or acquisitions. The company said that Cambridge life science community will provide Baxalta access to a range of innovations and collaboration partners. Baxalta has approximately 40 programs in development, and plans to launch 20 new products by 2020.
The center supports cross-functional, co-located teams including R&D, oncology, biosimilars, business development, corporate strategy, and customer operations, along with others that support or work closely with R&D. By the end of 2015, Baxalta expects to employ approximately 500 individuals at the Global Innovation Center. In addition, the company also operates a hemophilia treatment manufacturing facility in Milford, Massachusetts.